AD1058

AD1058 is an orally active, selective, and BBB-permeable inhibitor of ATR (IC50: 1.6 nM) . AD1058 exhibits anticancer activity by inhibiting tumor cell proliferation, inducing cell cycle arrest, and promoting apoptosis. AD1058 is suitable for research on advanced malignancies and brain metastases[1].

Product Specifications

CAS Number

[2907782-78-7]

UNSPSC

12352005

Target

AMPK; Apoptosis; ATM/ATR; mTOR; Src

Type

Reference compound

Related Pathways

Apoptosis; Cell Cycle/DNA Damage; Epigenetics; PI3K/Akt/mTOR; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/ad1058.html

Purity

98.11

Solubility

DMSO : 100 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=S(N1C=CC2=C(N3[C@H](C)COCC3)N=C(C4=C5C(NC=C5)=NC=C4)N=C21)(C)=O

Molecular Formula

C19H20N6O3S

Molecular Weight

412.47

References & Citations

[1]Liu Z, Jiang K, et al. Discovery of Preclinical Candidate AD1058 as a Highly Potent, Selective, and Brain-Penetrant ATR Inhibitor for the Treatment of Advanced Malignancies. J Med Chem. 2024 Aug 8;67 (15) :12735-12759.